Spectral Diagnostics Reported Earnings

Spectral Diagnostics (EDTXF) reported breakeven results on revenue of $0.45 million for the . . Revenue fell 23.64% compared to the same quarter a year ago.

Spectral Medical Inc. develops and commercializes theranostic treatment for severe sepsis. The company's products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral Medical Inc., formerly known as Spectral Diagnostics Inc., is headquartered in Toronto, Canada.